In a report released yesterday, Geoff Meacham from Barclays maintained a Sell rating on Regeneron (NASDAQ: REGN), with a price target of $290. The company’s shares closed yesterday at $292.41, close to its 52-week low of $288.16.
According to TipRanks.com, Meacham is a 3-star analyst with an average return of 3.6% and a 51.4% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, United Therapeutics, and Johnson & Johnson.
Regeneron has an analyst consensus of Hold, with a price target consensus of $405.85.
Find more picks by Best Performing Analysts >>
Based on Regeneron’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.51 billion and quarterly net profit of $478 million. In comparison, last year the company earned revenue of $1.32 billion and had a net profit of $249 million.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M.
